Essential Thrombocythemia
Hematology
Illness script · Hematology
Essential Thrombocythemia
Clonal myeloproliferative neoplasm with autonomous megakaryocyte proliferation causing sustained thrombocytosis (>450K/µL), risking thrombosis and hemorrhage.
This illness script for Essential Thrombocythemia covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.
01
Predisposing factors
- Bimodal: middle-aged/older adults (median ~60) AND young women (20s-30s)
- Slight female predominance
- JAK2 V617F mutation in ~55% of cases
- CALR mutation in ~25%; MPL mutation in ~5%
- No major environmental risk factors identified
- Family history of MPN slightly increases risk
02
Presentation
- Often asymptomatic; found incidentally on routine CBC
- Erythromelalgia: burning pain + erythema of hands/feet — classic microvascular symptom
- Arterial thrombosis predominates: stroke, TIA, MI, digital ischemia
- Venous thrombosis: Budd-Chiari, portal/splenic vein thrombosis
- Hemorrhage (epistaxis, GI bleed) at extreme thrombocytosis (>1,500K) due to acquired vWD
- Mild splenomegaly; pruritus less prominent than in polycythemia vera
03
Pathophysiology
- Clonal megakaryocyte proliferation → excess platelet production independent of thrombopoietin
- JAK2 V617F → constitutive JAK-STAT pathway activation → unregulated hematopoiesis
- CALR mutations activate MPL (thrombopoietin receptor) mimicking ligand binding
- Very high counts (>1,500K/µL) → acquired von Willebrand disease → paradoxical bleeding
04
Diagnostics
- CBC: sustained platelets >450,000/µL on two separate measurements
- Bone marrow biopsy (gold standard): clustered large megakaryocytes, no significant fibrosis or dysplasia
- JAK2 V617F first; if negative, test CALR then MPL
- Must exclude reactive thrombocytosis: check iron stores, CRP, ESR, spleen status
- BCR-ABL PCR/FISH to rule out CML; WHO criteria require exclusion of other MPNs
05
Management
- Low-risk (age <60, no prior thrombosis): low-dose aspirin alone
- High-risk (age ≥60 OR prior thrombosis): hydroxyurea + aspirin — first-line cytoreduction
- Interferon-alpha preferred in pregnancy (hydroxyurea is teratogenic)
- Anagrelide is second-line; avoid in cardiovascular disease (cardiac side effects)
- Avoid aspirin if platelets >1,500K — bleeding risk from acquired vWD outweighs benefit
06
Clinical pivots
How to separate this script from the look-alikes that show up on exams and on the wards.
Reactive thrombocytosis
Reactive thrombocytosis has an identifiable secondary cause (infection, iron deficiency, post-splenectomy), no driver mutation, and resolves with treatment.
Polycythemia vera
PV has elevated hematocrit/RBC mass and near-universal JAK2 V617F; ET has isolated thrombocytosis with normal red cell mass.
Primary myelofibrosis
Myelofibrosis shows leukoerythroblastic smear with teardrop cells and marked BM fibrosis on biopsy — absent in ET.
Chronic myelogenous leukemia
CML is BCR-ABL1 positive with marked leukocytosis and basophilia; ET lacks BCR-ABL and has isolated thrombocytosis.
Keep reading
Full library- Erythema MultiformeAcute, self-limited immune-mediated hypersensitivity reaction producing classic target skin lesions, most commonly triggered by HSV infection.
- Fibromuscular DysplasiaNon-inflammatory, non-atherosclerotic disease of medium-sized arteries causing stenosis, aneurysm, and dissection, most often in renal and carotid arteries.
Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.